Compare Revvity Inc (RVTY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Summit Therapeutics Inc — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Summit Therapeutics Inc for 16 Days on average.
| RVTY | SMMT | |
|---|---|---|
Market Cap | $16.98B | $13.71B |
Volume | 1,456,900 | 6,173,057 |
Sector | Health | Health |
52-Week High | $157.36 | $26.38 |
52-Week Low | $82.26 | $12.43 |
Typical Hold Time | 12 Days | 16 Days |
Enterprise Value | $19.30B | $13.04B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
